COMMUNIQUÉS West-GlobeNewswire

Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
05/11/2026
First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD) Presentation to take place on Monday, [...]
Resolution Therapeutics Announces Positive Interim Phase I/II EMERALD Data for Regenerative Macrophage Therapy RTX001 in End-Stage Liver Disease
05/11/2026
Six-month interim data showed a 42% relative risk reduction in death, liver transplant or hepatic decompensation versus an external control RTX001 was well tolerated with no infusion-related serious adverse reactions; [...]
CurePSP Names First Recipients of Biomarker Accelerator Program, Awarding Its Largest Research Grants to Date
05/11/2026
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CurePSP has awarded more than $1.4 million through its Biomarker Accelerator Program to three researchers working to find reliable biomarkers for progressive supranuclear [...]
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
05/11/2026
Ghent, Belgium – November 5, 2026 , Nov. 05, 2026 (GLOBE NEWSWIRE) -- MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines Collaboration [...]
Resalis Therapeutics Announces First-in-Human Data for RES-010 Demonstrating Safety and Tolerability with Early Weight Loss Signals
05/11/2026
The completed Phase 1a study data in healthy volunteers showed early signs of pharmacodynamic activity supporting further clinical evaluation of RES-010 The Phase 1b study in healthy overweight and moderately obese [...]
Rakovina Therapeutics to Present Brain-Penetrant ATR Inhibitor Data at the 31st Society for Neuro-Oncology Annual Meeting
05/11/2026
Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumours VANCOUVER, British Columbia, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS [...]
2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary Endpoint
05/11/2026
BEIJING, Nov. 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that results from [...]
Arcoma AB (publ) offentliggör att Eiffel Investment Group passerat 10 procent av aktierna och rösterna.
05/11/2026
PRESSRELEASE 2026-11-05 Arcoma AB (publ) offentliggör att Eiffel Investment Group passerat 10 procent av aktierna och rösterna. Arcoma AB (publ) ("Arcoma") har mottagit information från Eiffel Investment Group om att de [...]
LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook
05/11/2026
SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the third [...]
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
05/11/2026
- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat [...]
Privia Health Reports Strong Third Quarter and Year-to-Date 2026 Results
05/11/2026
YTD’26 Net Income of $25.6M, +85.9% from YTD’25 YTD’26 Adjusted EBITDA of $114.7M, +21.9% from YTD’25 Full-Year 2026 Guidance Raised to Above High End for All Key Financial Metrics Expands VBC Footprint with Acquisition [...]
ENOVIS Announces Third Quarter 2026 Results
05/11/2026
Third-quarter sales growth of 2% on a reported basis, 5% organic Third-quarter Reconstructive sales growth of 6% on a reported and organic basis Raising full-year 2026 guidance for adjusted EBITDA and adjusted EPS Board [...]
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
05/11/2026
Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 Strong U.S. demand for AQVESME in [...]
Oxford Brain Diagnostics Wins 2026 CNS Summit Innovation Showcase
05/11/2026
MRI-based CDM technology identified patients with MCI who progressed to dementia three times faster, offering drug developers a new tool for patient selection OXFORD, United Kingdom, Nov. 05, 2026 (GLOBE NEWSWIRE) -- [...]
Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of Growth
05/11/2026
Todd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and commercialization of [...]
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
05/11/2026
Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027 Company plans to add oxycodone/acetaminophen (commonly known as [...]
REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
05/11/2026
Egetis Therapeutics’ lead asset, EMCITATE ® , is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder, impacting approximately 1 [...]
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
05/11/2026
Quarterly net revenues of $290.8 million, an increase of 27.6% year-over-year Pu rified Cortrophin ® Gel net revenues of $138.7 million, an increase of 36.1% year-over-year Quarterly GAAP net income available to common [...]
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
05/11/2026
- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug (ATI-045) in Atopic [...]

Pages